drugset
drugset / Trial / NCT03723746

A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants

NCT03723746 ↗

Phase 1 Completed 74 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to assess the safety and tolerability of single and multiple day dose of JNJ-67670187 compared to placebo.

Timeline

Start
2018-10-25
Primary completion
2019-12-16
Completion
2019-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-67670187 Unknown — Oral

Indications

No indication recorded.